From SCRIP INTELLIGENCE: INTERVIEW: GSK's West Coast drug hunter builds relationships, seeks 'quirky' science
GlaxoSmithKline has established a presence in San Diego led by Damien McDevitt to enhance the UK-based pharmaceutical company's existing partnerships on the West Coast and build new relationships with scientists, research institutes and biotechnology companies from Southern California to Seattle, Washington.
Scrip spoke with Dr McDevitt about GSK's drug-hunting strategy during the Global Partnering Conference hosted by San Diego's biotech industry association Biocom on 26 and 27 February (scripintelligence.com, 28 February 2014). Having a business office on the West Coast puts the big pharma company closer to innovative platforms, drug targets and compounds. It also provides opportunities to access new technologies early and shape their success.
"We want to see companies and technologies earlier, before it becomes obvious," Dr McDevitt said. "We want to be part of the conversation by being here."
Subscribe to SCRIP today to read this story in full & access the complete SCRIP Intelligence subscription. Biocom members: save 10% on your subscription when you subscribe today.
From SCRIP INTELLIGENCE: Pharma-biotech collaborations: Eight themes from Biocom's Partnering Conference
Big pharma, small biotech and academic institutions are experimenting with new ways of working together, and San Diego's life science industry group Biocom invited deal makers to town on 26 and 27 February to share their ideas.
It's not terribly difficult to convince people to come to San Diego in the middle of winter, especially for meetings that overlook the famous Torrey Pines Golf Course and the Pacific Ocean. Whether it was the prospect of escaping the cold and snow or the lure of local entrepreneurs, Biocom managed to assemble agroup of key business development and venture capital executives to share their strategies at the Lodge at Torrey Pines.
The posh hotel is strategically located between the golf course, the beach and San Diego's largest biotech research groups – the Scripps Research Institute, Sanford-Burnham Medical Research Institute, Salk Institute and the University of California, San Diego, to name a few.
Click here to read this story in full.
Otonomy Appoints Robert Savel as Chief Technical Officer
Brings Extensive Experience Leading Manufacturing Operations and Quality Control for Marketed Drug Products
SAN DIEGO, February 25, 2014 -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Robert Savel as chief technical officer. Mr. Savel brings more than 15 years of experience in managing technical operations for marketed drug products, including manufacturing and quality control. He will be replacing Gerald Wroblewski, who is retiring.
Epistem Announces Opening of US Laboratory
Epistem Holdings Plc (LSE: EHP), Manchester, UK, the biotechnology and personalised medicine company, today announced that it has opened a US laboratory based in Baltimore, Maryland. The laboratory will support the expansion of Epistem’s contract research division within the US. The US laboratory is currently offering histology and immunohistochemistry (IHC) services to a range of US clients, expanding upon the success of the GcLP and GLP compliant UK laboratory. The experienced and skilled technical team have already developed IHC protocols for a panel of over 150 antibodies which are available to clients worldwide.
From Politico: Medical Technology: Long-term Solutions to Reduce the Economic Burden of Disease
By Stephen J. Ubl, President and CEO, AdvaMed | 2/28/14 12:00 AM EDT
Advancements in medical devices and diagnostics are helping patients worldwide to live longer, healthier and more independent lives. These life-changing innovations are helping the blind to see, the deaf to hear and the wounded to walk. And thanks to medical technology, patients are now able to survive conditions that just a few years ago would have been a death sentence.